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While the number of current smokers has declined due to legal and regulatory measures and public health 
awareness, cigarette smoking remains the top risk factor for many diseases, including cancers originated from 
various tissues. Meanwhile, thyroid cancer incidence has increased significantly in the USA. Former 
epidemiology studies have investigated the association between smoking and risk of thyroid cancer, and 
interestingly results from these studies have shown that smoking has protective effect on risk of thyroid cancer. 
Studies have tapped into genetic polymorphisms and their association with thyroid cancer (and its subtypes) to 
further examine the susceptibility of certain gene variants carriers, and these studies have covered multiple 
SNPs of genes, which belong to relevant pathways including xenobiotic metabolism, DNA damage response and 
repair. Neither did the results from these studies form a consistent opinion about which SNPs/genes/pathways 
are associated with thyroid cancer among specific population, nor did they give confirmed explanation about 
molecular mechanisms supporting their results. In the current study, we investigated the association between 
smoking and thyroid cancer with stratification for 299 SNPs of 340 DNA repair genes. Study subjects included 
440 cases diagnosed between 2010 and 2011 from Yale Cancer Center’s Rapid Case Ascertainment Shared 
Resource, and 465 pairing controls in Connecticut. The study was conducted to test the hypothesis that genetic 
variations in DNA repair genes modify the association between smoking and risk of thyroid cancer. RPA1 
(replication protein A1 gene) rs11867830 have shown statistically significant effect modification for smoking-
papillary thyroid cancer association. ALKBH3 (alkB homolog 3, alpha-ketoglutarate-dependent dioxygenase 
gene) rs10768995 and rs197371 significantly modified such association for follicular thyroid cancer subtypes. 
MAD2L2 (MAD2 mitotic arrest deficient-like 2 gene) rs747863, RAD54L (RAD54-like (S. cerevisiae) gene) 
rs10789488, TDG (thymine DNA glycosylase gene) rs2700505, rs322106, and rs322107 are demonstrated to 
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Introduction 
Epidemiology of Thyroid Cancer 
Thyroid cancer is the development of malignant tumor of the gland in front of the neck that normally produces 
thyroid hormones which are important to the normal regulation of the metabolism of the body1. The cancer 
often presents as a nodule, and while many of thyroid gland nodules are benign, the overall incidence of cancer 
in a nodule is 12%-15%. Main types of thyroid cancer include papillary thyroid cancer (PTC), follicular thyroid 
cancer (FTC), anaplastic thyroid cancer (ATC), and para-follicular C-cell-derived medullary thyroid carcinoma 
(MTC). The prevalence of these subtypes among thyroid cancer are approximately 80%, 10%, 3%, and 4%2. 
According to the Surveillance, Epidemiology and End Results Program of National Cancer Institute3, estimated 
number of new cases of thyroid cancer in 2015 is 62,450 (47,230 in women, and 15,220 in men), which accounts 
for 3.8% of all new cancer cases, and the number of new deaths associated with thyroid cancer in 2015 is 
estimated to be 1,950 (1,080 women and 870 men), accounting for 0.3% of all cancer deaths. Thyroid cancer is 
ranked as the 8th most common type of cancer in the general population following breast cancer, lung and 
bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma, and non-Hodgkin 
lymphoma. It is most common in women than men, and is frequently diagnosed among people aged from 45 to 
54. 
Established risk factors for thyroid cancer includes radiation exposure4-6, family history of thyroid disease, 
female gender and Asian race7. Many epidemiology studies also investigated the association of thyroid cancer 
with cigarette. While it is generally believed that thyroid cancer is not a smoking related neoplasm, several 
studies results indicated a negative association8. Mack et al.9 conducted a pooled analysis of 14 case control 
studies including 2725 thyroid cancer cases and 4776 controls in USA, Europe and Asia. Conditional logistic 
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regression with stratification shows that thyroid cancer risk was reduced in current smokers (OR = 0.6, 95% CI = 
0.6–0.7) and former smokers (OR = 0.9, 95% CI = 0.8–1.1).  A population-based case control study , Rossing et 
al.10 ,also showed that a history of ever having smoked more than 100 cigarettes was associated with a reduced 
risk of PTC (OR = 0.7, 95% CI = 0.5–0.9); such reduction was most evident in current smokers (OR = 0.5, 95% CI = 
0.4–0.7). Galanti et al.11 showed that women who started smoking before the age of 15 experienced a markedly 
reduced in risk (OR, 0.38%; 95% CI, 0.18-0.80). Researchers have given explanations for the negative association. 
Smoking might decrease the thyroid-stimulating hormone (TSH) level which lead to a decreased growth rate of 
thyroid epithelial cell12. A second possible explanation is that smoking decreases the risk of thyroid cancer by 
decreasing smokers’ body weight compared to non-smokers. Some researchers also hypothesized that smoking 
is related to the decreased level of estrogen, since the thyroid cancer has a higher prevalence among female 
than male. However, these researches have not yet given clear sufficient illustrations in terms of the microscopic 
and genetic mechanism of the negative association. 
Genetics of Thyroid Cancer and Mechanism of DNA Damage in Thyroid Cells 
Different gene mutations are found and investigated for different subtypes of thyroid cancer. Multiple 
endocrine neoplasia type 2 (MEN2), as one kind of hereditary syndromes, are caused by a mutation in the RET 
proto-oncogene, and could be categorized into three subtypes (MEN2A, familial medullary thyroid carcinoma 
(FMTC), and MEN2B) which all impart high risk of developing medullary thyroid cancer. The BRAF gene mutation 
has been much investigated for its association with papillary thyroid carcinoma. Yoram et al.14 applied 
polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15 and among the 35 papillary 
thyroid carcinomas examined, 24 (69%) were found to carry a thymine-adenine transversion at nucleotide 1796 
in the BRAF gene (T1796A). Nikiforova et al.15 reported that BRAF mutation is identified not only in papillary 
carcinomas (38%) but also in poorly differentiated carcinomas (13%) and anaplastic carcinomas (10%), but none  
cases were identified in follicular, Hurthele cell and medullary carcinomas. Other classical oncogenic genetic 
alterations commonly seen in thyroid cancer include RAS and RET/PTC rearrangement PPARγ fusion oncogene.  
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Similar to other sites, DNAs in thyroid gland also face both endogenous and exogenous attacks. Endogenous 
damages mainly are damages from Reactive Oxygen Species (ROS), including peroxides, superoxides, hydroxyl 
radicals and singlet oxygens. According to K Krohn et al.16, tobacco smoking would possibly lead to exacerbate 
oxidative stress in thyrocytes and increase mutagenesis by thiocyanate-ion-induced blockage of the iodine 
transport. Bio-synthesis of TSH requires high concentrations of hydro peroxides and oxidized iodine. While hydro 
peroxides give rise to highly reactive hydroxyl radicals that would cause damages including oxidized bases and 
abasic sites, decreased concentration of iodine actually stimulated generation of excess amount of H2O2. Low 
iodine levels and markers of increased thyroid functionality suggest activation of H2O2 generation, which could 
result in DNA damage and somatic mutation.  
Exogenous damages include damages from aromatic substances attacks, which would possibly lead to DNA 
intercalation, the insertion of specific molecules (ligands) between the planar bases of DNA. Typical ligands 
include polycyclic aromatics, which are contained in smoke and tar of cigarettes. However, the process of DNA 
intercalation with toxic substances are mostly likely to happen at the sites of lung cells, and metabolism process 
of tobacco smoking chemicals shows little evidence that those DNA adducts could happen at thyrocytes. 
Smoking related DNA Repair in Thyroid Cancer 
Many studies have investigated the association between a biomarker of oxidative stress to DNA repair, urinary 
8-hydroxydeoxyguanosine (8-OHdG), and smoking 17-20. However, although in pathological changed thyrocytes 
there possibly exists excess oxidative stress that would lead to DNA impairment and production of 8-OHdG, 
these studies do not dig into relationship between these interaction and thyroid cancer. The reason is that 
smoking is not yet a considered and clearly understood as a thyroid cancer related risk factor, so these studies 
do not look into genotyped thyroid cancer patients and the specifically smoking induced repairing mechanisms. 
An important perspective worth looking into is the biological metabolism of carcinogen contained in smoking 
and the sites that these chemicals would actually have an effect on DNAs.  
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Genetic Polymorphism & GXE interaction 
While genetic susceptibility researches focus on the association between gene variations and risk of thyroid 
cancer, gene-environmental researches instead investigate the effect modification on the association between 
smoking and risk of thyroid cancer, which refers to the testing of whether carrying wild-type homozygous or 
variant genotypes would result in significantly different associations of such. Despite this difference, genetic 
susceptibility researches might offers evidence to support interpretations of effect modification. When 
genetically stratified associations are compared with the raw association between the exposure and outcomes, 
such comparison would give light to investigation on the genetic susceptibility among specific subgroup of 
population, for example in this case, smokers.  
There have been studies which investigated genetic polymorphisms and risks of thyroid cancer subtypes. In 
some studies, ionize radiation is acknowledged as a recognized risk factor for thyroid cancer and researchers 
have tested the hypothesis that polymorphisms in genes, which are potentially associated with ionize radiative 
attacks from psychological perspectives, are associated with risks of thyroid cancer. Genes of such kind could 
belong to different pathways (including DNA damage response21, homologous recombination22, xenobiotic 
metabolism23, and DNA base excision repair24 etc.), and they were separately studied. As for smoking, Bufalo et 
al.25 put xenobiotic metabolism related genes (CYP and GST) and smoking equally into one multiple logistic 
regression model as risk factors to differentiated thyroid cancer subtypes and found inverse correlation between 
cigarette smoking (P=0.0385) and CYP1A1m1 germline inheritance (P=0.0237) with risks of papillary carcinomas. 
Similarly, for xenobiotic metabolism related genes, Lemos26 et al. simply apply the Pearson’s chi-square test to 
examine the differences of CYP2D6 poor metabolizer genotype and allele between papillary thyroid cancer 
patients and controls and found a lower frequency of homozygous poor metabolizer genotype carriers (1.6% vs. 
5.5%, P=0.037, OR=0.28 (95% CI: (0.09, 0.93))) and CYP2D6*4 allele carriers (13.4% vs. 21.7%, P=0.002, OR=0.56 
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(95% CI: (0.39, 0.80))) in the patient group, which implicates the protective effect of the CYP2D6 poor 
metabolizer genotype possibly because of the decrease amount of metabolized chemical intermediates.  
Different from pre-assuming and selecting specific genes, Neta et al. 27 extended the number and scope of the 
candidate genes belonging to multiple pathways related to genomic integrity. The study progressively examined 
the association of SNPs, gene regions, and genomic integrity pathways with risk of papillary thyroid cancer, and 
found that while after statistical multiple comparisons adjustment, SNPs, gene regions and overall DNA repair 
pathways do not significantly associate with risks of thyroid cancer, direct reversal of DNA damage and other 
conserved damage response genes sub-pathways demonstrate significant association. As a gene that belongs to 
direct reversal of DNA damage pathway, MGMT SNPs were reported to be significantly associated with papillary 
thyroid cancer with a p-value<0.0005 in Neta et al27 . While no study has reported associations between MGMT 
polymorphisms and thyroid cancer, some studies have been conducted on its polymorphisms and other 
carcinomas. Zhang et al.28 reported that although there were no significant associations between candidate 
MGMT SNPs (rs1711646, rs1625649, rs1803965, rs12917) and susceptibility to squamous cell carcinoma of the 
head and neck (SCCHN) when studied individually, statistically significant risks were found among carriers of 3 or 
4 combined genotypes16195 CC, 16286CC, 45996 GT+TT, and 46346 CA+AA genotypes compared to those 
carrying less than 2 (OR=1.27, 95% CI: (1.11, 2.96)). Ma et al.29 reported protective effects of several SNPs 
variants on MGMT on esophageal squamous cell carcinoma (ESCC) carcinogenesis and progression. Akbari et 
al.30 performed a similar study in a SCCHN high risk region in Iran and found the G>A substitution in MGMT 
rs7087131 variant was associated with decreased risk of ESCC in Turkmen (OR=0.26, P=0.01). The function of 
MGMT as a gene encoding a protein which catalyzes transfer of methyl groups from O(6)-alkylguanine and other 
methylated moieties of the DNA to its own molecule for gene protection31, and the fact that hypermethylation 
of multiple genes and genes promoter has been reported to be significantly associated with papillary thyroid 
cancer32,33, as well as the methylation effect of PAHs (Polycyclic aromatic hydrocarbons) from smoking34,35,36,37, 
might help explain MGMT’s effect modification in our study. Moreover, the methylation of MGMT itself might 
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inhibit its direct reversal repairing function32,33. However, the SNPs on MGMT in our studies which significantly 
modify the smoking-thyroid cancer association have not yet been reported as risk factors in genetic 
polymorphism researches, and no former studies have investigated the gene environment interaction for 
thyroid cancer.  
Materials and methods 
Population selection 
Cases were histologically confirmed, incident thyroid cancer patients [papillary (ICD-O-3: 8050, 8052, 8130, 
8260, 8340–8344, 8450, and 8452), follicular (ICD-O-3: 8290, 8330–8332, and 8335), medullary (ICD-O-3: 8345, 
8346, and 8510), or anaplastic (ICD-O-3: 8021)] from Connecticut diagnosed between 2010 and 2011. Eligible 
patients were aged between 21 and 84 years at diagnosis, had no previous diagnosis of cancer, with the 
exception of nonmelanoma skin cancer, and were alive at the time of interview. Cases were identified through 
the Yale Cancer Center’s Rapid Case Ascertainment Shared Resource (RCA). The RCA acts as an agent of the 
Connecticut Tumor Registry. The Connecticut Public Health Code requires reporting of all cancer cases in 
licensed hospitals and clinical laboratories to the Connecticut Tumor Registry. RCA field staff are assigned 
geographically to survey all of the state’s nonpediatric hospitals to identify newly diagnosed cases. Information 
on the cases identified in the field is sent regularly to the RCA data-entry staff, who enter, verify, and screen 
these data against the Connecticut Tumor Registry database. The Connecticut Tumor Registry has reciprocal 
reporting agreements with cancer registries in all adjacent states (and Florida) to identify residents from 
Connecticut with cancer diagnosed and/or treated in these states. Cases and controls were frequency-matched 
by age (± 5 years). Distributions of age, sex, and race were similar between the participants and nonparticipants 




SNPs Selection and Genotyping 
 After interview 440 thyroid cancer cases and 465 controls donated samples of venipuncture whole 
blood.  Peripheral blood leukocyte DNA was extracted using the Qiagen phenol-chloroform extraction kit 
according to standard manufacturer protocol.  DNA was then genotyped using a custom-made Golden Gate 
Illumina assay.  Genotyping data were successfully obtained for all 440 thyroid carcinoma cases (including 373 
papillary thyroid carcinoma cases and 54 follicular subtype) and 465 controls using this protocol.  The Golden 
Gate assay included analysis of 299 single-nucleotide polymorphisms (SNPs) in 340 gene regions involved in DNA 
repair, based on statistical significance previously demonstrated in the 2011 analysis of Neta et al.  (Included in 
our analysis were all individual SNPs from Neta et al. that had demonstrated psnp<0.1, as well as all additional 
SNPs associated with gene regions with pgene<0.1.)  Quality-control duplicate samples were also included in the 
genotyping platform.  All duplicate samples yielded a concordance rate of ≥99%, with no statistically-significant 
difference observed between replicated samples. Hardy-Weinberg equilibrium (HWE) was assessed in controls 
for each SNP using a chi-square test. SNPs with a p-value >0.00001 from the chi-square test were considered to 
be in HWE. 
All procedures were performed in accordance with a protocol approved by the Human Investigations Committee 
at Yale and the Connecticut Department of Public Health. After approval by the hospitals and by each 
participant’s physician (cancer cases), or after selection through random sampling (control population), potential 
participants were approached by letter and then over the phone. Those who agreed were interviewed by 
trained study interviewers, either at their homes or at a convenient location.  
With regard to smoking exposure, the participants were asked about the following smoking status and history: 
(a) current smoking status, (b) pack-years of smoking, (c) numbers of cigarettes smoked, (d) smoking duration 
and (e) age started smoking. The participants were asked whether they had ever smoked. If a participant 
answered ‘yes’, he/she was asked how old he/she started smoking, as well as the total number cigarette he/she 
smoke per year. ‘Exposure’ to smoking was defined as ever smoking behavior of the respondent, where ‘non-
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exposure’ was defined as non-smoking behavior. Odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated using unconditional logistic regression models to estimate the associations between smoking and the 
risk of thyroid cancer by histologic subtype and tumor size, and to control for potential confounders. Other 
confounding factors included would be: age, sex, and education level, family history of thyroid cancer, previous 
benign thyroid disease, BMI, alcohol consumption, and radiation treatment. Decisions on the covariates to be 
included in the final model were based on a greater than 10% change in the risk estimates. All analyses were 
carried out using SAS (version 9.4; SAS Institute Inc., Cary, North Carolina, USA). 
Statistical Analysis 
Unconditional logistic regression models were used to estimate the associations of smoking and genetic 
variation of DNA repair pathway genes with risk of thyroid cancer and its subtypes (papillary and follicular). With 
the assumption that the SNPs we studied were dominant mutation, we combined heterozygous and 
homozygous variant genotypes of all 299 genes extracted from the studied population to increase statistical 
power. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated adjusting for age, gender, race, 
education, and BMI index.  
We created and included the interaction terms of single nucleotide polymorphisms (SNPs) into the logistic 
regression model to see whether the relationship between smoking and thyroid cancer risk would be modified 
by genetic variation. We put the interaction term, along with allele genotype variable, smoking and other 
potential confounding factors into the regression model, and examine the p-value of the coefficient of the 
interaction term. We used an a priori significance level of 0.01 for each test rather than a Bonferroni correction 
because the Bonferroni correction is overly conservative when hypothesis tests are correlated. A significance 
level of 0.01 will increase the type I error rate to the point of certainly identifying some false positive findings. 
However, it will also reduce the number of false negative findings, and thus the actual alpha is likely to be 
substantially less than the nominal alpha is this case. If the allele genotype variable is found to have a significant 
p-value of less than 0.01, we then recognize the SNPs as having significant effect modification on the association 
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between smoking and thyroid cancer. For these genes we stratified the association between smoking and 
thyroid cancer by genotype (wild-type homozygous vs. heterozygous + homozygous variant), and the smoking 
would be identified as having significant association with thyroid cancer if the p-value of its coefficient in the 
unconditional logistic regression model would be less than 0.05. 
 
Results 
Of the 440 patients with thyroid cancer, the majority were diagnosed with papillary thyroid cancer (373, 
84.77%), followed by follicular (54, 12.27%), medullary (11, 2.50%), anaplastic (1, 0.23%) and others (1, 0.23%). 
The average age at diagnosis of thyroid cancer is 51 years old. The patient group has a much higher proportion 
of female (80.91%) compared to the control group (68.82%). Cases are more likely coming from lower income 
families, more obese than controls, and have family history of thyroid cancer among first-degree relatives. 
Moreover, we observed that the proportion of prior benign thyroid disease is lower among cases, and they are 
less likely to smoke. The characteristics of the studied population are shown in Table 1.  
Similar to former epidemiological studies, exposure to smoking has the trend to negatively affect the risk, but 
did not reach significance (OR=0.80, 95% CI: 0.59, 1.09; p-value: 0.15). When we analyzed the data by 
histological subtypes, similar association were observed for papillary and follicular thyroid cancer, while the 
protective association for papillary subtype (OR =0.87, 95% CI: 0.64-1.19; p-value=0.37) is weaker compared to 
follicular (OR=0.69, 95% CI: 0.36-1.31; p-value=0.25), however, these associations are not statistically significant. 
 
Table 1. Characteristics of thyroid cancer cases and controls 
  Cases(440) Controls(465)  
    [N(%)] [N(%)] p-value 
Age(years)    
 Mean(SD) 50.94(12.14) 54.07(13.08) 0.0006 
 0-40 89(20.23%) 71(15.27%)  
 41-50 121(27.50%) 126(27.10%)  
 51-60 133(30.23%) 119(25.59%)  
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 61-70 75(17.05%) 92(19.98%)  
 >70 22(5.00%) 57(12.26%)  
Sex   <0.0001 
 Male 84(19.09%) 145(31.18%)  
 Female 356(80.91%) 320(68.82%)  
Race   0.3706 
 White 396(90.00%) 427(91.83%)  
 Black 16(3.64%) 20(4.30%)  
 Asians 7(1.59%) 5(1.08%)  
 Others 21(4.77%) 13(2.80%)  
Family income   0.3016 
 <$25,000 27 (6.19%) 43 (9.35%)  
 $25,000~$89,999 121 (27.75%) 113 (24.57%)  
 >$90,000 155 (35.55%) 174 (37.83%)  
 Confidential 114 (26.15%) 115 (25.00%)  
 Not sure 19 (4.36%) 15 (3.26%)  
 Missing=9    
Years of education   0.0021 
 Grades School 4(0.91%) 3(0.65%)  
 High School 118(26.94%) 75(16.30%)  
 Tech/Trade School 30(6.85%) 23(5.00%)  
 College/Univeristy 176(40.18%) 226(49.13%)  
 Grad & Prof School 97(22.15%) 120(26.09%)  
 Others 13(2.97%) 13(2.83%)  
 Missing=7    
Family history of thyroid cancer among first-degree relatives 0.0309 
 Yes 54(12.27%) 37(7.96%)  
 No 386(87.73%) 428(92.04%)  
Prior benign thyroid disease  <0.001 
 Yes 56(12.73%) 453(97.42%)  
 No 384(87.27%) 12(2.58%)  
BMI(kg/m2)   0.0003 
 0-25 143(32.72%) 192(42.01%)  
 26-30 136(31.12%) 155(33.92%)  
 >30 158(36.16%) 110(24.07%)  
 Missing=11    
Smoking   0.2412 
 Never 303(69.18%) 302(65.51%)  
 Ever 135(30.82%) 159(34.49%)  
 Missing=6    
Subtypes    
 Papillary 373(84.77%)   
 Follicular 54(12.27%)   
 Medullary 11(2.50%)   
 Anaplastic 1(0.23%)   




a Benign thyroid disease included hyperthyroidism, hypothyroidism, goiter, thyroid nodules, and thyroid adenoma. 
b Ever smoking was defined as ever smoked a total of 100 cigarettes or more. 
 
 
Table 2. Association between smoking and thyroid cancer   
    Overall   
Smoking Exposurea Controls Cases OR (95% CI) P-Value 
 Never 302 303   
  Ever 159 135 0.80 (0.59-1.09) 0.15 
a Ever smoking was defined as ever smoked a total of 100 cigarettes or more. 
 
Table 3. Association between smoking and thyroid cancer subtypes 
        Papillary     Follicular   
Smoking 
Exposurea  Controls Cases OR(95%CI) p-value Controls Cases OR(95%CI) p-value 
 Never  346 256   556 39   
  Ever   179 115 0.87 (0.64-1.19) 0.37 279 15 0.69 (0.36-1.31) 0.25 
a Ever smoking was defined as ever smoked a total of 100 cigarettes or more. 
 
Among all 299 DNA repair pathway SNPs studied, statistically significant association for genetic polymorphisms 
were observed in 5 for thyroid cancer overall, while 1 for papillary and 2 for follicular thyroid cancer. Results are 
presented in Table 4. These genes were identified first through effect modification analysis, and then through 
genotype stratification. Only genes with significant p-values in both effect modification analysis and at least one 
stratum of genotypes were considered as having gene-environment interaction.  
5 SNPs in 3 gene regions showed significant gene-environment interaction for overall cases of thyroid cancer. 
Significant decreased risks of thyroid cancer overall were observed among smokers with wild-type homozygous 
genotype in 1 gene MAD2L2 rs747863 CC (OR=0.62, 95% CI (0.43, 0.89), p=0.0095) compared with its 
heterozygous/homozygous variant TC/TT (OR=1.61, 95% CI (0.84, 3.08), p=0.1482). Significantly decreased risks 
of thyroid cancer overall were observed among smokers with heterozygous/homozygous variant genotypes 
(CC/TC) in RAD54L rs10789488 (OR=.., 95% CI (), p=), while its wild-homozygous smoking carriers have an 
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insignificant increased risk of having thyroid cancer (OR=.., 95% CI (), p=).  3 SNPs on the gene TDG (rs2700505, 
rs322107, rs322106) also demonstrated modifying effect.  
Only 1 SNP in 1 gene region significantly modifies the association between smoking and the risk of papillary 
thyroid cancer. Significantly decreased risks of papillary thyroid cancer were observed among smokers carrying 
heterozygous/homozygous variant genotypes in RPA1 rs11867830 TC/CC (OR=0.45, 95% CI: (0.25, 0.81), p-
value=0.08), while the carriers of the wild-type homozygous genotype RPA1 rs11867830 TT (OR=1.15, 95% CI: 
(0.78, 1.68), p-value=0.478) who smoke have an insignificantly increased risk, which differ from the overall 
pooled population of study.  
2 SNPs in 2 gene regions have demonstrated effect modification for the follicular thyroid cancer subtype. 
Significant decreased risks of this subtype associated with smoking were observed among carriers of 
heterozygous/homozygous variant genotype of RECQL rs4762 GC/CC (OR=0.33, 95% CI: (0.13, 0.83), p-
value=0.019) and ALKBH3 rs1973717 TC/TT (OR=0.32, 95% CI: (0.13, 0.82), p-value=0.018), while the 
homozygous genotype carriers of these two genes have an insignificantly increased risk (RECQL rs4762 
(OR=2.48, 95% CI: (0.80, 7.71), p-value=0.117; ALKBH3 rs1973717 (OR=2.45, 95% CI (0.78, 7.65), p-value=0.124). 
Results are shown in Table 5 and 6. 
Table 4. Stratified association between smoking and overall cases of thyroid cancer by SNPs 
Single Nucleotide 
Polymorphism 
Never Smoke Ever Smoke 
OR (95% CI) a p-value Interaction Term p-value b Case Control OR=1.00 Case Control 
MAD2L2 C>T rs747863         
CC 222 212  89 121 0.62 (0.43, 0.89) 0.0095 0.01 
TC/TT 80 90  45 38 1.61 (0.84, 3.08) 0.1482  
RAD54L T>C rs10789488         
TT 174 193  84 79 1.17 (0.78, 1.75) 0.4525 0.0021 
CC/TC 128 109  50 80 0.45 (0.27, 0.75) 0.0022  
TDG A>G rs2700505         
AA 114 138  68 59 1.44 (0.89, 2.34) 0.1381 0.0076 
AG/GG 186 164  67 100 0.54 (0.35, 0.81) 0.0032  
TDG G>A rs322107         
GG 200 212  107 106 1.06 (0.74, 1.52) 0.736 0.0072 
AG/GG 102 90  28 53 0.31 (0.16, 0.62) 0.0009  
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TDG A>G rs322106         
AA 201 212  107 106 1.06 (0.74, 1.51) 0.7593 0.0057 
AG/GG 101 90  27 53 0.29 (0.14, 0.59) 0.0005  
Abbreviations: CI: confidence interval; OR: odds ratio. 
a P value for the interaction between smoking and genotype variations in a logistic regression model, with adjustment for 
age, sex, race, education, family income, and BMI index 
b Logistic regression model with adjustment for age, sex, race, education, family income, and BMI index  
 
Table 5. Stratified association between smoking and papillary thyroid cancer by SNPs 
Single Nucleotide 
Polymorphism 
Never Smoke Ever Smoke 
OR (95% CI) a p-value Interaction Term p-Value b Case Control OR=1.00 Case Control 
RPA1 T>C  rs11867830         
TT 84 119  149 242 1.15 (0.78, 1.68) 0.4778 0.007 
TC/CC 30 60  107 107 0.45 (0.25, 0.81) 0.0078  
Abbreviations: CI: confidence interval; OR: odds ratio. 
a P value for the interaction between smoking and genotype variations in a logistic regression model, with adjustment for 
age, sex, race, education, family income, and BMI index 
b Logistic regression model with adjustment for age, sex, race, education, family income, and BMI index 
 
Table 6. Stratified association between smoking and follicular thyroid cancer by SNPs 
Single Nucleotide 
Polymorphism 
Never Smoke Ever Smoke 
OR (95% CI) a p-value Interaction Term  p-value b Case Control OR=1.00 Case Control 
ALKBH3 G>C rs10768995         
GG 107 9  218 8 2.48 (0.80, 7.71) 0.1168 0.0076 
GC/CC 171 6  346 31 0.33 (0.13, 0.83) 0.0187  
ALKBH3 C>T rs1973717         
CC 112 9  229 8 2.45 (0.78, 7.65) 0.1243 0.0082 
TC/TT 167 6  331 31 0.32 (0.13, 0.82) 0.0175  
Abbreviations: CI: confidence interval; OR: odds ratio. 
a P value for the interaction between smoking and genotype variations in a logistic regression model, with adjustment for 
age, sex, race, education, family income, and BMI index 
b Logistic regression model with adjustment for age, sex, race, education, family income, and BMI index 
Interestingly, the significant SNPs identified for overall thyroid cancer cases did not overlap with any of those for 
papillary or follicular subtypes, and the identified SNPs for these 2 subtypes also are totally different.  
Discussion 
This study addressed potential modifying effect of SNPs in DNA repair genes on the association between 
smoking and the risk of differential and overall thyroid cancer. The results of our population-based case-control 
study are consistent with former epidemiological researches which report reduced risk of thyroid cancer among 
tobacco consumers, while the association is not statistically significant. By further looking into the genetic level, 
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we found that genetic variations of specific DNA repair genes could have modified the association between 
smoking and thyroid cancer, and it helped explain the individual susceptibility to thyroid cancer among smoking 
population. These effect modifications were observed among genes for multiple DNA repair pathways (shown in 
Table 7) instead of a single pathway (such as base excision repair, strand breaking repair etc.), and the 
discovered genes and their mutations are not shown to be associated with thyroid cancer in former studies. The 
underlying repairing mechanisms of these genes variants against tobacco exposure are not yet supported by 
sufficient scientific research and evidence and the outcomes in our study might only be significant from a 
statistical perspective rather than a genetic and psychological one.  
Table 7.  DNA repair genes with variant genotypes and affected susceptibility to thyroid cancer types 
Gene symbol Gene Full name  Repair pathway and function of encoded protein Significant thyroid cancer types 
RAD54L RAD54-like (S.cerevisiae) 
Homologous recombination; Helps homologous 
recombination related repair of DNA double-
strand breaks. 
Overall 
TDG thymine DNA glycosylase 
Base excision repair; Helps remove thymine 
moieties from G/T mismatches on DNA single 
strand 
Overall 
MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) 
DNA polymerase; Makes up the mitotic spindle 
assembly checkpoint that prevents the onset of 
anaphase 
Overall 
RPA1 replication protein A1 
Nucleotide excision repair; Binds and stabilizes 
single-stranded DNA, intermediates that from 
during DNA replication or upon DNA stress 
Papillary only 
ALKBH3 
alkB homolog 3, alpha-
ketoglutarate-dependent 
dioxygenase 
Direct reversal of damage; Helps defend DNA 
against alkylating agents, similar to MGMT Follicular only 
 
Despite genetic susceptibility studies, there has neither been investigation into the DNA repair gene-smoking 
interaction and risk of thyroid cancer, nor any stratified association between smoking and thyroid cancer by 
SNPs. Former studies only identified radiation as a risk factor, but smoking as an unclear protective effect. The 
reason behind these counterintuitive outcomes may be that radiation exposes direct effects on thyroid and it 
generates carcinogenicity by causing DNA damages which the repairing mechanism might not be sufficient to 
eliminate. In contrast, while carcinogenic chemicals from smoking would possibly not circulate to thyroid cells, 
the carcinogens stimulate the systematic DNA repairing mechanisms of the human body, and indirectly decrease 
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the risk of getting thyroid cancer. Since there is no reference literature on this kind of gene-environment 
interaction, we could only refer to those genetic susceptibility studies for thyroid cancer to look for genes that 
we have identified in our research, and if there is not we tried to seek evidence in other types of cancer.  
RAD54L 
RAD54L (RAD54-like (S. cerevisiae)), encodes a protein which is involved in the homologous recombination and 
repair of DNA double-strand breaks by inducing a DNA topological changes37, 38, which shares similarity with 
Saccharomyces cerevisiae Rad54. As pointed out by Sturgis et al.39, RAD54 polymorphisms that result in amino 
acid change have been identified, but reported allele frequencies are less than 2%40. Therefore, there are not 
many studies investigating RAD54L/RAD54 polymorphism and its relation with thyroid cancer, and the SNP 
RAD54L rs10789488 in our study has never been identified as risk factor of any carcinogenesis before.  Carling et 
al.41 examined the a well characterized set of parathyroid adenomas for inactivating mutations in the RAD54 
gene and fully sequenced all 18 exons, including the intron–exon junctions of the RAD54 gene in 12 parathyroid 
adenomas with LOH at chromosome 1p, and were unable to detect any mutational aberrations or homozygous 
deletions in the gene. Li et al.42 examined the effect of RAD54L C157T SNP on the survival time of pancreatic 
cancer, and reported that pancreatic cancer carriers of variant genotypes of RAD54L rs1048771 (CT/TT) have 
significantly shorter survival time, and the SNP in this study is an independent risk factor of survival. The authors 
pointed out that RAD54L rs1048771 is a functionally silent polymorphism so its effect on pancreatic cancer 
might due to its linkage to other SNPs on RAD54L or other genes.  Similarly, after identifying a silent C/T 
transition at nucleotide 2290 in exon 18 on RAD54L, Leone et al.43 reported that the frequency of the rare allele -
T and heterozygotes for the 2290C/T polymorphism in the blood of Spanish meningioma patients and in the 
Ecuadorian meningioma tumors was significantly higher, but there is lack of evidence that the SNP has any 






ALKBH3, as another gene related to direct reversal of damage which also demonstrate its modifying effect for 
several of its SNPs on smoking and thyroid cancer association, little is known about the relationship between its 
polymorphism and cancer. In the genetic susceptibility study of Neta et al.27, SNP ALKBH3 rs10838192 T>C is 
significantly associated with papillary thyroid cancer. Carriers of the heterozygous TC and homozygous variant 
CC genotypes have both respectfully higher risks of having papillary thyroid cancer (TC: OR=1.74(1.25-2.41); CC: 
OR=2.33(1.05-5.17). However, in this study, neither ALKBH3 rs10768995 nor rs1973717, which have both shown 
significant effect modification in our study for follicular cancer, is not significantly associated with development 
with papillary thyroid cancer (p-values > 0.01). Despite the different cancer subtypes, this situation could be 
explained by that even these SNPs are not directly related to thyroid cancer, they can still modify the association 
between a risk factor and the carcinoma.  
RPA1 
RPA1 is a gene region which helps maintain integrity in DNA replication process by binding and stabilization of 
single-stranded DNA. Cipollini et al.45 reported that RPA1 rs1131636 T>C polymorphism is very unlikely 
associated with the risk of differentiated thyroid cancer. In Neta et al.27 it shows a similar result that the 
examined RPA1 SNPs (including the rs11867830 T>C which has shown significant effect modification for papillary 
cancer) are not significantly associated with papillary cancer subtype. Michiels et al.46 found an increasing risk 
for Head and Neck cancer development for RPA1 haplotype 2 carriers (OR=1.60, 95% CI: 1.02-2.47). Han et al.47 
reported the SNP-SNP interaction and its association with breast cancer and found that the presence of RPA1 
rs11078676 (AG) together with ERCC rs50872 was strongly associated with increased risk of breast cancer 






TDG, encoded a protein that belongs to the TDG/mug DNA glycosylase family. Thymine-DNA glycosylase (TDG) 
removes thymine moieties from G/T mismatches by hydrolyzing the carbon-nitrogen bond between the sugar-
phosphate backbone of DNA and the mispaired thymine, thymine from C/T and T/T mispairings when at lower 
activity, and also uracil and 5-bromouracil from mispairings with guanine. This enzyme plays a central role in 
cellular defense against genetic mutation caused by the spontaneous deamination of 5-methylcytosine and 
cytosine. Krzesniak ´ et al.48 reported that the non-silent polymorphism of TDG (199: Ser. 367: Met) did not show 
any significant association with lung cancer risk. 
MAD2L2 
MAD2L2 (MAD2 mitotic arrest deficient-like 2) encodes a DNA polymerase which makes up the mitotic spindle 
assembly checkpoint that prevents the onset of anaphase. Suga et al.49 screened 999 SNPs in 137 candidate 
genes on 399 subjects to have found that carriers of haplotypes CG in MAD2L2 would have decreased risk of 
early skin reactions for irradiated breast. However, none of former studies have reported MAD2L2 rs747863 as 
significant disease risk indicators.  
In fact, while the gene regions might explain such effect modification to some extent, it could not explain the 
changes brought by multiple SNPs on a gene region. Interestingly, among the significant SNPs identified in our 
study, MAD2L2 rs747863, RAD54L 10789488, RPA1 rs11867830, ALKBH3 rs10768995 and rs1973717 are located 
in intro regions of the genes, which means they would not be used for mRNA translation or furtherly result in 
functional amino acid changes. TDG rs2700505 is located within an exon but belong to the 5’ UTR (5 prime 
untranslated region) and would not be translated. TDG rs322106 and rs322107 both are categorized as 
upstream variant 2KB, and it is very likely that they would not induce any functional changes neither since they 
refer to changes within 1000 bp of the transcript start site on the 5’ side, and they are not included into the 
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mRNA transcription. However, it has now been acknowledged that many important mutations are located in the 
intron regions, and they might have indirect impacts on splicing and mRNA transcription. While we could not 
exclude the possibility that the interaction between these SNPs and other functional gene changes would 
explain such gene-environment interaction, genetic susceptibility studies have already shown lack of evidence 
that these SNPs would bring out substantial changes. Therefore, the results shown in our research remain to be 
examined and further researches are still needed.  
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